Volatility Characterises Asia Pacific Q211 Pharmaceuticals & Healthcare BERs

BMI View: Asia Pacific's attractiveness to multinational drugmakers is faltering. BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs), which assess countries according to their risk/reward profile, reveal that the region's score decreased from 53.1 out of 100 in Q111 to 52.5 in Q211 - a drop of 1.13%. Ratings decreases were also seen in Western Europe (-0.93%) and the Americas (-2.20%). Meanwhile, increases were seen in Central and Eastern Europe (+0.19%) and Middle East/Africa (+3.45%).

To read the full article, please choose one of the following options: